N/A
N=100
Impact of Pharmaceutical Care in Diabetics Patients
Diabetes Mellitus Type 2
Bottom Line
View on ClinicalTrials.gov: NCT01580904 ↗Enrolled (actual)
100
Serious AEs
73.0%
Results posted
Feb 2017
Primary outcome: Primary: Glycated Hemoglobin — 7.2; 7.1 percent (%)
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Intervention: Pharmaceutical Care (Behavioral)
- Age
- Adult, Older Adult · 30+ yrs
- Sex
- All
- Sponsor
- Universidade Estadual da Paraiba
- Primary completion
- Dec 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Glycated Hemoglobin |
7.2; 7.1 | — |
| PRIMARY Fasting Glycemia |
157.7; 159.3 | — |
| SECONDARY Total Cholesterol |
209.9; 191.1 | — |
| SECONDARY LDL Cholesterol |
131.0; 110.8 | — |
Summary
The monitoring of diabetics by the pharmacist may contribute to the effectiveness of drug treatment and to improve their quality of life. This study will measure the impact of pharmacotherapeutic follow-up in diabetic patients. This will be a clinical trial, single blind, controlled, randomized, conducted in two units of pharmacies in Brazil. Only in the intervention group will be held the pharmacotherapeutic follow using a methodology called the practice of pharmaceutical care, which identifies and resolves problems related to drugs. The primary outcome is glycated hemoglobin, and secondary outcomes are baseline glucose, total cholesterol and its fractions (for example LDL), all these measures will be made in the intervention group and control group. Patients will be followed for 24 weeks, and the outcomes will be assessed up to 24 weeks. There will be a confidence interval of 95% and a significance of p <0.05, and will use the Student t test, chi-square analysis of variance (ANOVA) and others if necessary. Expects good results and serve as a model for other researchers.
Eligibility Criteria
Inclusion Criteria:Inclusion criteria:
- patients aged 30 years,
- diagnosed with type 2 diabetes,
- to make use of oral antidiabetic agents with or without insulin
Exclusion Criteria
those who had infectious diseases during the research
- missed three consecutive interviews,
- suspended the hypoglycemic drug and medical order
Data sourced from ClinicalTrials.gov (NCT01580904). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.